Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (14210)
All Articles published online
|
Publishing Process of This Article
|
Mar 14, 2021 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva Kh, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27(10): 959-975 [PMID: 33776366 DOI: 10.3748/wjg.v27.i10.959] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v27/i10/959.htm |
| Number | Citing Articles |
| 1 |
志宇 高. Research Progress on the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Advances in Clinical Medicine 2024; 14(04): 1192 doi: 10.12677/acm.2024.1441142
|
| 2 |
Wenkang Gao, Zhonglin Li, Huikuan Chu, Hang Yuan, Lilin Hu, Lin Yao, Li Zhang, Weijun Wang, Rong Lin, Ling Yang. Pharmacotherapy for Liver Cirrhosis and Its Complications. 2022; : 81 doi: 10.1007/978-981-19-2615-0_6
|
| 3 |
Yulia V. Kotovskaya. Non-alcoholic fatty liver disease and cardiovascular risks: A review. Consilium Medicum 2023; 25(4): 253 doi: 10.26442/20751753.2023.4.202275
|
| 4 |
Yuan Zhou, Ruoqi Li, Yingyi Zheng, Meiying Song, Shanshan Zhang, Yunxia Sun, Mengying Wei, Xiang Fan. Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.854790
|
| 5 |
Zi-Lin Ren, Chang-Xiang Li, Chong-Yang Ma, Dan Chen, Jia-Hui Chen, Wen-Xiu Xu, Cong-Ai Chen, Fa-Feng Cheng, Xue-Qian Wang. Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling. International Journal of Molecular Sciences 2022; 23(21): 13045 doi: 10.3390/ijms232113045
|
| 6 |
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski. Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation. International Journal of Molecular Sciences 2023; 24(11): 9677 doi: 10.3390/ijms24119677
|
| 7 |
A. O. Bueverov. Hepatobiliary continuum: non-alcoholic fatty liver disease, cholelithiasis ... what else?. Meditsinskiy sovet = Medical Council 2021; (15): 68 doi: 10.21518/2079-701X-2021-15-68-76
|
| 8 |
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov Analysis. Diabetes, Metabolic Syndrome and Obesity 2024; : 545 doi: 10.2147/DMSO.S448476
|
| 9 |
Marina V. Maevskaya, Yulia V. Kotovskaya, Vladimir T. Ivashkin, Olga N. Tkacheva, Ekaterina A. Troshina, Marina V. Shestakova, Valeriy V. Breder, Natalia I. Geyvandova, Vladimir L. Doshchitsin, Ekaterina N. Dudinskaya, Ekaterina V. Ershova, Khava B. Kodzoeva, Ksenia A. Komshilova, Natalia V. Korochanskaya, Alexander Yu. Mayorov, Ekaterina E. Mishina, Maria Yu. Nadinskaya, Igor G. Nikitin, Nana V. Pogosova, Aida I. Tarzimanova, Minara Sh. Shamkhalova. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv 2022; 94(2): 216 doi: 10.26442/00403660.2022.02.201363
|
| 10 |
V. T. Ivashkin, M. V. Maevskaya, M. S. Zharkova, Yu. V. Kotovskaya, O. N. Tkacheva, E. A. Troshina, M. V. Shestakova, I. V. Maev, V. V. Breder, N. I. Gheivandova, V. L. Doshchitsin, E. N. Dudinskaya, E. V. Ershova, Kh. B. Kodzoeva, K. A. Komshilova, N. V. Korochanskaya, A. Yu. Mayorov, E. E. Mishina, M. Yu. Nadinskaya, I. G. Nikitin, N. V. Pogosova, A. I. Tarzimanova, M. Sh. Shamkhalova. Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2022; 32(4): 104 doi: 10.22416/1382-4376-2022-32-4-104-140
|
| 11 |
A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology 2022; 12(1): 155 doi: 10.1016/j.jceh.2021.08.017
|
| 12 |
Nahum Méndez-Sánchez, Shreya C. Pal, Jacqueline Córdova-Gallardo. How far are we from an approved drug for nonalcoholic steatohepatitis?. Expert Opinion on Pharmacotherapy 2023; 24(9): 1021 doi: 10.1080/14656566.2023.2206953
|
| 13 |
Na Li, Cheng Zhao, Pingnan Zhang, Songting Wu, Xiaotan Dou, Saifei Xu, Xiaoqi Zhang, Chunyan Peng, Ying Xie, Shuling Huang, Lin Zhou, Yonghua Shen, Lei Wang, Jinglin Wang, Chenggong Yu. The Role of Gut Microbiota associated Metabolites in Digestive Disorders. Engineered Regeneration 2024; doi: 10.1016/j.engreg.2024.04.003
|
| 14 |
Yafang Yang, Ligang Yang, Jiale Wu, Jing Hu, Min Wan, Jindi Bie, Jiaxin Li, Da Pan, Guiju Sun, Chao Yang. Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis. Clinical Nutrition 2024; 43(6): 1224 doi: 10.1016/j.clnu.2024.04.004
|
| 15 |
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh. Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma. Frontiers in Endocrinology 2023; 14 doi: 10.3389/fendo.2023.1150360
|
| 16 |
Anlu Wang, Baoyi Guan, He Zhang, Hao Xu. Danger-associated metabolites trigger metaflammation: A crowbar in cardiometabolic diseases. Pharmacological Research 2023; 198: 106983 doi: 10.1016/j.phrs.2023.106983
|
| 17 |
Ye Rin Park, Hae Lee Lee, Ji Ye Hyun, Jieun Choi, Ji Hyun Moon, Byung Yong Kim, Seung-Jo Yang, Je Hee Lee, Byoung Kook Kim, Tae-Sik Park, Ki Tae Suk, Do Yup Lee, Heenam Stanley Kim.
Systemic multiomics evaluation of the therapeutic effect of
Bacteroides
species on liver cirrhosis in male mice
. Microbiology Spectrum 2023; 11(6) doi: 10.1128/spectrum.05349-22
|
| 18 |
Marcin Kosmalski, Rafał Frankowski, Sylwia Ziółkowska, Monika Różycka-Kosmalska, Tadeusz Pietras. What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). Journal of Clinical Medicine 2023; 12(5): 1852 doi: 10.3390/jcm12051852
|
| 19 |
Xiaohan Xu, Kyle L. Poulsen, Lijuan Wu, Shan Liu, Tatsunori Miyata, Qiaoling Song, Qingda Wei, Chenyang Zhao, Chunhua Lin, Jinbo Yang. Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduction and Targeted Therapy 2022; 7(1) doi: 10.1038/s41392-022-01119-3
|
| 20 |
T Milivojac, M Grabež, A Krivokuća, U Maličević, M Gajić Bojić, Đ Đukanović, S Uletilović, N Mandić-Kovačević, T Cvjetković, M Barudžija, N Vojinović, A Šmitran, Lj Amidžić, MP Stojiljković, M Čolić, M Mikov, R Škrbić. Ursodeoxycholic and chenodeoxycholic bile acids attenuate systemic and liver inflammation induced by lipopolysaccharide in rats. Molecular and Cellular Biochemistry 2024; doi: 10.1007/s11010-024-04994-2
|
| 21 |
M. V. Maevskay. Ursodeoxycholic acid: unique properties and clinical applications. Meditsinskiy sovet = Medical Council 2023; (8): 96 doi: 10.21518/ms2023-136
|
| 22 |
Chunye Zhang, Ming Yang. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers 2021; 13(15): 3740 doi: 10.3390/cancers13153740
|
| 23 |
Tao Zhang, Yingli Nie, Jiliang Wang. The emerging significance of mitochondrial targeted strategies in NAFLD treatment. Life Sciences 2023; 329: 121943 doi: 10.1016/j.lfs.2023.121943
|
| 24 |
S. N. Mekhtiev, O. A. Mekhtievа, O. M. Berko. Current perspective on the problem of cholesterol polyps of the gallbladder in patients with nonalcoholic fatty liver disease. Meditsinskiy sovet = Medical Council 2022; (14): 70 doi: 10.21518/2079-701X-2022-16-14-70-78
|
| 25 |
Anastasiya M. Kaneva, Evgeny R. Bojko. Fatty liver index (FLI): more than a marker of hepatic steatosis. Journal of Physiology and Biochemistry 2024; 80(1): 11 doi: 10.1007/s13105-023-00991-z
|
| 26 |
Xin Ding, Xu He, Bulang Tang, Tian Lan. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies. Chinese Medicine 2024; 19(1) doi: 10.1186/s13020-024-00894-1
|
| 27 |
Qingyi Mao, Beibei Lin, Wenluo Zhang, Yu Zhang, Yu Zhang, Qian Cao, Mengque Xu. Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1371574
|
| 28 |
Li Rong, Junyan Zou, Wei Ran, Xiaohong Qi, Yaokai Chen, Hongjuan Cui, Jinjun Guo. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Frontiers in Endocrinology 2023; 13 doi: 10.3389/fendo.2022.1087260
|
| 29 |
Sahar H. Elhini, Engy A. Wahsh, Ahmed A. Elberry, Nadia F. El Ameen, Ahmed Abdelfadil Saedii, Shereen Mahmoud Refaie, Asmaa A. Elsayed, Hoda M. Rabea. The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients. Pharmaceuticals 2022; 15(12): 1516 doi: 10.3390/ph15121516
|
| 30 |
M. Imawari, M. Nagase, I. Yu. Torshin, O. A. Gromova. An open-label, controlled trial of the clinical effects of Laennec® in patients with nonalcoholic steatohepatitis or cirrhosis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 2023; 16(3): 447 doi: 10.17749/2070-4909/farmakoekonomika.2023.206
|